二氢嘧啶脱氢酶（DPYD）基因分型及剂量调整对氟嘧啶治疗候选患者的临床影响
Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment.
作者信息
Hernández-Guío Ana, Ángel Calleja-Hernández Miguel, Corno-Caparrós Andrés, Zayas-Soriano Marta, Bernabéu-Martínez Mª Ángeles, Gutiérrez-Nicolás Fernando
机构信息
Department of Pharmacy, San Juan de Alicante University Hospital, N-332, s/n, 03550, Sant Joan d'Alacant, Alicante, Spain.
Department of Pharmacy, Virgen Macarena University Hospital, Sevilla, Av. Dr. Fedriani, 3, 41009, Seville, Spain.
出版信息
Heliyon. 2024 Dec 2;10(23):e40808. doi: 10.1016/j.heliyon.2024.e40808. eCollection 2024 Dec 15.
Abstract
Image 1.
摘要
图1。
相似文献
[1]
[2]
Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2021
[3]
[4]
[5]
[6]
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Clin Colorectal Cancer. 2022-9
[7]
[8]
[9]
[10]
本文引用的文献
[1]
[2]
[3]
Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.
Clin Pharmacol Ther. 2023-10
[4]
[5]
[6]
[7]
Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
Asian Pac J Cancer Prev. 2022-9-1
[8]
[9]
[10]
Zotero 插件